Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia
The Journal of Clinical Endocrinology & Metabolism · 2024
DOI: 10.1210/clinem/dgad514 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Myrto Eleni Flokas und 4 weiteren Autor:innen. Beteiligte Einrichtung: Children's National Hospital, Washington, DC 20010, USA. Hauptthemen laut MEDLINE: Adrenal Hyperplasia, Congenital, Puberty, Precocious. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Context
Children with congenital adrenal hyperplasia (CAH) are at risk for early puberty. Gonadotropin-releasing hormone analog (GnRHa) is frequently used and can decrease bone mineral density (BMD).
Objective
Our aim was to investigate the effect of GnRHa therapy on BMD in a longitudinal study of patients with CAH spanning both childhood and adulthood. Design and Setting Sixty-one patients with classic CAH due to 21-hydroxylase deficiency (20 treated with GnRHa) were followed with dual-energy X-ray absorptiometry (DXA) scans at puberty onset, attainment of adult height, and during early adulthood. Main Outcome Measures Whole body, lumbar spine, femoral neck, total hip, and distal radius BMD z-score at adult height. Longitudinal BMD and adult height were also assessed.
Results
Twenty patients received GnRHa for an average of 4.5 ± 2 years. There were no differences in BMD between GnRHa-treated and -untreated groups at adult height for all sites. Overall, the follow-up DXA during early adulthood showed decreases in BMD z-scores for whole body (P = .01), lumbar spine (P < .0001), femoral neck (P = .06), total hip (P = .009), and distal radius (P = .05). GnRHa treatment correlated with improved height outcomes compared to predicted height at puberty onset after adjusting for midparental height (P = .02). Patients in both groups achieved similar adult height.
Conclusion
In children with CAH, GnRHa does not compromise BMD. However, BMD decreases with time and during the second and third decades of life is a possible effect of chronic supraphysiologic glucocorticoids. Children with CAH who experience early puberty benefit from GnRHa treatment as evidenced by the positive effect on height.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Children's National Hospital, Washington, DC 20010, USA.
- The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD 20892-1932, USA.
- The National Institutes of Health Clinical Center, Bethesda, MD 20892-1932, USA.
ORCID-Profile: Myrto Eleni Flokas, Ninet Sinaii, Deborah P Merke
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Flokas, M. E., Wakim, P., Kollender, S., Sinaii, N., & Merke, D. P. (2024). Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgad514
Vancouver
Flokas ME, Wakim P, Kollender S, Sinaii N, Merke DP. Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgad514
BibTeX
@article{Flokas2024,
author = {Flokas, Myrto Eleni and Wakim, Paul and Kollender, Sarah and Sinaii, Ninet and Merke, Deborah P},
title = {Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
doi = {10.1210/clinem/dgad514}
}
EUVIMED